Draupnir Bio

Draupnir Bio is a Danish biotechnology company founded in 2017 with the slogan "Bringing innovative therapies to patients." The company is focused on developing oral, small molecule degraders of extracellular pathogenic proteins, which is a pioneering approach in the field of targeted protein degradation (TPD). This approach targets lysosome receptors and has the potential to revolutionize the TPD field by extending the potential of TPD to both extracellular and membrane-bound proteins. The company is led by a highly experienced team of pharma and biotech industry leaders and is a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany. Draupnir Bio has received a $33.00M Venture Round investment on 31 October 2019 from a syndicate of leading European investors including High-Tech Gründerfonds, Novo Holdings, Gilde Healthcare, Inkef. As a biotechnology company operating in the Biotechnology, Health Care, and Pharmaceutical industries, Draupnir Bio is dedicated to harnessing the natural machinery of the lysosome to develop innovative therapies and address unmet medical needs. With its differentiated proprietary technology platform, the company is poised to make significant advancements in the field of TPD, potentially offering new solutions for diseases that have historically been highly challenging to target with conventional therapies.